KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Nektar Therapeutics (NKTR) Total Current Liabilities (2016 - 2025)

Historic Total Current Liabilities for Nektar Therapeutics (NKTR) over the last 16 years, with Q3 2025 value amounting to $66.3 million.

  • Nektar Therapeutics' Total Current Liabilities fell 183.92% to $66.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $66.3 million, marking a year-over-year decrease of 183.92%. This contributed to the annual value of $61.4 million for FY2024, which is 1976.05% up from last year.
  • Per Nektar Therapeutics' latest filing, its Total Current Liabilities stood at $66.3 million for Q3 2025, which was down 183.92% from $71.4 million recorded in Q2 2025.
  • In the past 5 years, Nektar Therapeutics' Total Current Liabilities registered a high of $140.0 million during Q3 2021, and its lowest value of $50.7 million during Q2 2023.
  • In the last 5 years, Nektar Therapeutics' Total Current Liabilities had a median value of $68.2 million in 2022 and averaged $79.1 million.
  • In the last 5 years, Nektar Therapeutics' Total Current Liabilities tumbled by 6724.7% in 2021 and then skyrocketed by 3534.71% in 2025.
  • Nektar Therapeutics' Total Current Liabilities (Quarter) stood at $85.2 million in 2021, then dropped by 19.95% to $68.2 million in 2022, then decreased by 24.83% to $51.3 million in 2023, then rose by 19.76% to $61.4 million in 2024, then increased by 8.05% to $66.3 million in 2025.
  • Its Total Current Liabilities stands at $66.3 million for Q3 2025, versus $71.4 million for Q2 2025 and $70.9 million for Q1 2025.